CT laser system and dedicated breast scanner show promise as adjunctive imaging methods
Mammography is far from perfect, and a range of techniques may serve in a supporting role to this omnipresent but notoriously fallible breast cancer screening tool. One of the newest on the scene is conebeam CT, which gathers volumetric data using a digital flat-panel detector packed into a small-parts imaging unit. Three-D images display 360 degrees worth of breast anatomy, up to 300 images, with no more radiation than a two-view mammography scan.
The University of Rochester in New York developed and patented a conebeam CT system for breast imaging. The university installed a clinical version of the dedicated breast unit in June. Commercial release of the scanner is uncertain as FDA requirements for approval are not yet known. Initially, the system will be used to assist diagnosis and not for breast screening. For this purpose, requirements are expected to be less stringent. The price will be between $700,000 and $800,000.
"We don't feel a large-scale trial is required as we are not going for screening," said John Neugebauer, CEO of the Koning Corporation.
The company has been commercializing the unit with the help of more than $8 million in grants from the National Institutes of Health.
CT laser mammography (CTLM), another supportive technique, is able to detect greater blood flow, which is a sign of cancer, with a radiation-free energy source. At the 2006 European Congress of Radiology, Dr. Daniel Flory, a radiologist at the University of Vienna, presented encouraging results after evaluating 410 patients with 421 breast lesions with a CTLM system. The overall sensitivity and specificity were 66% and 63%, respectively. The sensitivities for invasive and noninvasive carcinoma were 73% and 49%, respectively.
"The results are comparable to other adjunctive techniques," Flory said.
The researchers used a laser device from Imaging Diagnostic Systems in Plantation, FL. It is commercially available in Europe, Canada, and the Middle East but does not have FDA approval for use in the U.S. The manufacturer aspires to make its domestic debut in 2007.
Elastography, an ultrasound-based method of measuring the elastic property of tissue, is getting a fresh look. At the ECR, researchers from Britain and France showed the efficacy of the technique. They said it could reduce the rate of biopsies of benign breast lesions, whose elastic property is not as stiff as malignant tissue. Siemens Medical Solutions is planning the commercial release of an elastography-enabled system later this year.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.